Evolus, Inc. recently announced that the US Food and Drug Administration (FDA) has approved its lead product, Jeuveau, for the temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Evolus, Inc. is headquartered in Newport Beach, CA. Jeuveau is expected to be available throughout the US at physician offices starting in Spring 2019.
Indications: Jeuveau is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Dosage/administration: 0.1 mL (4 units) of Jeuveau is administered by intramuscular injection into each of 5 sites, for a total dose of 20 units.
Adverse reactions: The most common adverse reactions are (6.1): headache (9.3%), eyelid ptosis (2%), upper respiratory tract infection (3%), and increase in white blood cell count (1%).
Evolus receives FDA approval for Jeuveau prabotulinumtoxinA-xvfs for injection. [news release]. Newport Beach, CA: Evolus, Inc. February 1, 2019. https://www.firstwordpharma.com/node/1622573. Accessed February 6, 2019.